Retevmo Selpercatinib RET Fusion Positive NSCLC Thyroid Review 2026
Author: Critical Kare PharmaPrecision Oncology Desk
On October 21, 2026, molecular oncology panels emphasized the definitive frontline role of Retevmo® (Selpercatinib 40 mg and 80 mg hard capsules) developed by Eli Lilly for RET fusion-positive NSCLC and RET-altered thyroid carcinomas.
Following landmark Phase 3 LIBRETTO-431 evidence, Retevmo demonstrated significant progression-free survival superiority over platinum-based chemotherapy plus pembrolizumab, establishing targeted RET inhibition as the undisputed first-line standard.
Through Critical Kare Pharma, certified genuine packs of Retevmo Selpercatinib Capsules are supplied directly to tertiary oncology centers and named patients globally.
LIBRETTO-431 & Intracranial Disease Control
- PFS Superiority: Median PFS reached 24.8 months with selpercatinib compared to 11.2 months with chemotherapy plus pembrolizumab.
- CNS Penetration: 82% intracranial response rate in patients with measurable baseline brain metastases.
- Dosing: Weight-based: 160 mg orally twice daily for patients ≥50 kg; 120 mg twice daily for patients <50 kg.
Global Sourcing via Critical Kare Pharma
Delivered under US FDA Personal Import, UK Special Access, and ANVISA corridors with full batch authenticity records.
